Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LILAC Phase 3 study of abelacimab in high-risk atrial fibrillation patients unsuitable for oral anticoagulation
CTR20232698Phase 3Active
- Sponsor
- Anthos Therapeutics
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of abelacimab in Atrial fibrillation (AFib), atrial flutter (AFL), sponsored by Anthos Therapeutics. Started Nov 2023; status: active.
02
Drugs
abelacimab
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on CTR20232698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232698.